(VIANEWS) – Capital Southwest Corporation (CSWC), Corcept Therapeutics Incorporated (CORT), Catalyst Pharmaceuticals (CPRX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Capital Southwest Corporation (CSWC)
41.3% sales growth and 11.92% return on equity
Capital Southwest Corporation is a business development company specializing in credit and private equity and venture capital investments in middle market companies, mezzanine, later stage, mature, late venture, emerging growth, buyouts, recapitalizations and growth capital investments. It does not invest in startups, publicly traded companies, real estate developments, project finance opportunities, oil and gas exploration businesses, troubled companies, turnarounds, and companies in which significant senior management is departing. In lower middle market, the firm typically invests in growth financing, bolt-on acquisitions, new platform acquisitions, refinancing, dividend recapitalizations, sponsor-led buyouts, and management buyouts situations. The investment structures are Unitranche debt, subordinated debt, senior debt, first and second lien debt, and preferred and common equity. The firm makes equity co-investments alongside debt investments, up to 20% of total check and only makes non-control investments. It prefers to invest in Industrial manufacturing and services, value-added distribution, healthcare products and services, business services, specialty chemicals, food and beverage, tech-enabled services and SaaS models. The firm seeks to invest in energy services and products, industrial technologies, and specialty chemicals and products. Within energy services and products, the firm seeks to invest in each segment of the industry, including upstream, midstream and downstream, excluding exploration and production with a focus on differentiated products and services, equipment and tool rental, consumable products, and drilling and completion chemicals. Within industrial technologies, it seeks to invest in automation and process controls, handling and packaging equipment, industrial filtration and fluid handling, measurement, monitoring and testing, professional tools, and sensors and instrumentation. Within and specialty chemicals and products, the firm seeks to invest in businesses that develop and manufacture highly differentiated chemicals and products including adhesives, coatings and sealants, catalysts and absorbents, cosmeceuticals, fine chemicals, flavors and fragrances, performance lubricants, polymers, plastics and composites, chemical dispensing and filtration equipment, professional and industrial trade consumables and tools, engineered solutions for HVAC, plumbing, and electrical installations, specified high performance materials for fire protection and oilfield applications. It may also invest in exceptional opportunities in building products. The firm seeks to invest in the United States. The firm seeks to make investments ranging from $5 to $25 million in securities. It seeks to make equity investments up to $5 million and debt investments between $5 million and $20 million and co-invest in transaction size upto $40 million. It prefers to invest in companies with revenues approaching above $10 million, profitable operations, historical growth rate of at least 15 percent per year. . Within the lower middle market, it seeks to invest in with less than $15 million in EBITDA and also opportunistically invests in the upper middle market, generally defined as companies with EBITDA in excess of $50 million. In addition to making direct investments, the firm allocates capital to syndicated first and second lien term loans in the upper middle market. Criteria for Upper Middle Market Syndicated 1st Lien is EBITDA Size more than $30 million, Closing Leverage greater than 4 times, investment hold size between $5 million and $7 million, investment yield greater than 6.5%. Criteria for Upper Middle Market Syndicated 2nd Lien is EBITDA Size more than $50 million, Closing Leverage greater than 6 times, investment hold size between $5 million and $7 million, investment yield greater than 9%. It prefers to take a majority and minority stake. The firm has the flexibility to hold investments for very long period in its portfolio companies. It may also invest through warrants. The firm prefers to take Board participation in its portfolio companies. Capital Southwest Corporation was founded on April 19, 1961 and is based in Dallas, Texas.
Earnings Per Share
As for profitability, Capital Southwest Corporation has a trailing twelve months EPS of $1.85.
PE Ratio
Capital Southwest Corporation has a trailing twelve months price to earnings ratio of 12.36. Meaning, the purchaser of the share is investing $12.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.92%.
2. Corcept Therapeutics Incorporated (CORT)
21.6% sales growth and 19.55% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $0.8.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 33.42. Meaning, the purchaser of the share is investing $33.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.55%.
Volume
Today’s last reported volume for Corcept Therapeutics Incorporated is 97267 which is 86.89% below its average volume of 742390.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 78.6% and 64.3%, respectively.
Sales Growth
Corcept Therapeutics Incorporated’s sales growth is 24% for the current quarter and 21.6% for the next.
Moving Average
Corcept Therapeutics Incorporated’s value is under its 50-day moving average of $26.74 and higher than its 200-day moving average of $25.42.
3. Catalyst Pharmaceuticals (CPRX)
19.3% sales growth and 20.06% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.55.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.28. Meaning, the purchaser of the share is investing $24.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.06%.
Sales Growth
Catalyst Pharmaceuticals’s sales growth is 74.1% for the ongoing quarter and 19.3% for the next.
Moving Average
Catalyst Pharmaceuticals’s value is higher than its 50-day moving average of $13.17 and under its 200-day moving average of $13.94.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Catalyst Pharmaceuticals’s EBITDA is 3.99.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $13.35 at 19:22 EST, way below its 52-week high of $22.11 and way higher than its 52-week low of $11.09.
4. Brown & Brown (BRO)
15% sales growth and 15.71% return on equity
Brown & Brown, Inc. markets and sells insurance products and services in the United States, Bermuda, Canada, Cayman Islands, Ireland, and the United Kingdom. It operates through four segments: Retail, National Programs, Wholesale Brokerage, and Services. The company offers builders risk, group medical and pharmaceutical, property, commercial auto, homeowners, reinsurance, crop and hail, inland marine, retirement benefit, cyber, disability, risk mitigating warranty products, directors and officers, management liability, errors and omissions, medical stop loss, term life, excess liability, personal auto, umbrella, general liability, prescription drug, workers compensation, and group dental insurance products. It also provides professional liability and related package insurance products for dentistry, legal, eyecare, insurance, financial, physicians, and real estate title professionals, as well as supplementary insurance-related products for weddings, events, medical facilities, and cyber liability; homeowners and personal property policies, residential earthquake, and private passenger automobile and motorcycle coverage; commercial and public entity-related programs; and flood insurance, commercial difference-in-conditions, all-risk commercial property, coastal property programs, lender-placed solutions, sovereign Indian nations, and parcel insurance. In addition, it provides markets and sells excess and surplus commercial insurance products, such as personal lines, homeowners, yachts, jewelry, commercial property and casualty, commercial automobile, garage, restaurant, builder's risk, and inland marine lines; and third-party claims administration and medical utilization management services in the workers' compensation and all-lines liability arenas, as well as Medicare Set-aside, Social Security disability, Medicare benefits advocacy, and claims adjusting services. The company was founded in 1939 and is headquartered in Daytona Beach, Florida.
Earnings Per Share
As for profitability, Brown & Brown has a trailing twelve months EPS of $2.63.
PE Ratio
Brown & Brown has a trailing twelve months price to earnings ratio of 28.21. Meaning, the purchaser of the share is investing $28.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.71%.
Yearly Top and Bottom Value
Brown & Brown’s stock is valued at $74.19 at 19:22 EST, below its 52-week high of $75.14 and way higher than its 52-week low of $52.82.
Moving Average
Brown & Brown’s worth is above its 50-day moving average of $71.09 and way higher than its 200-day moving average of $66.40.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Oct 30, 2023, the estimated forward annual dividend rate is 0.52 and the estimated forward annual dividend yield is 0.7%.
Sales Growth
Brown & Brown’s sales growth is 9.5% for the present quarter and 15% for the next.
Previous days news about Brown & Brown(BRO)
- According to Zacks on Monday, 11 December, "Consistent operational results have been aiding Brown & Brown in generating solid cash flows for deployment in growth initiatives.", "Brown & Brown, Inc.’s (BRO Quick QuoteBRO – Free Report) subsidiary, Brown & Brown Dealer Services, has purchased ABS Risk, LLC and ABS Operations, LLC, together known as ABS. "
5. Expedia Group (EXPE)
9.6% sales growth and 21.9% return on equity
Expedia Group, Inc. operates as an online travel company in the United States and internationally. The company operates through Retail, B2B, and trivago segments. Its brand portfolio includes Brand Expedia, a full-service online travel brand with localized websites; Hotels.com for marketing and distributing lodging accommodations; Vrbo, an online marketplace for the alternative accommodations; Orbitz; Travelocity; Wotif Group; CheapTickets; ebookers; Expedia; Hotwire; CarRentals.com; Classic Vacations; and Expedia Cruise. The company's brand portfolio also comprises Expedia Partner Solutions, that offers private label and co-branded products through third-party websites; and Egencia that provides travel services to businesses and corporate customers. In addition, its brand portfolio consists of Trivago, a hotel metasearch website, which send referrals to online travel companies and travel service providers from hotel metasearch websites. Further, the company provides loyalty programs, hotel accommodations and alternative accommodations, and advertising and media services. It serves leisure and corporate travelers, that includes travel agencies, tour operators, travel supplier direct websites and call centers, consolidators and wholesalers of travel products and services, online portals and search websites, travel metasearch websites, mobile travel applications, and social media websites, as well as traditional consumer ecommerce and group buying websites. The company was formerly known as Expedia, Inc. and changed its name to Expedia Group, Inc. in March 2018. Expedia Group, Inc. was founded in 1996 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Expedia Group has a trailing twelve months EPS of $5.46.
PE Ratio
Expedia Group has a trailing twelve months price to earnings ratio of 26.41. Meaning, the purchaser of the share is investing $26.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.9%.
Yearly Top and Bottom Value
Expedia Group’s stock is valued at $144.19 at 19:22 EST, below its 52-week high of $145.83 and way higher than its 52-week low of $82.39.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.6%, now sitting on 12.57B for the twelve trailing months.
Moving Average
Expedia Group’s value is way higher than its 50-day moving average of $114.34 and way above its 200-day moving average of $106.08.
Sales Growth
Expedia Group’s sales growth is 10% for the current quarter and 9.6% for the next.
6. Alamo Group (ALG)
9% sales growth and 16.47% return on equity
Alamo Group Inc. designs, manufactures, distributes, and services agricultural and infrastructure maintenance equipment for governmental and industrial use worldwide. The company offers hydraulically-powered and tractor-mounted mowers, including boom-mounted mowers; other cutters and replacement parts for heavy-duty and intensive uses; and heavy duty, tractor- and truck-mounted mowing, and vegetation maintenance equipment and replacement parts. It also provides truck-mounted air vacuum, mechanical broom, and regenerative air sweepers; pothole patchers; leaf collection equipment and replacement brooms; parking lot and street sweepers; excavators; catch basin cleaners and roadway debris vacuum systems; truck-mounted vacuum trucks, combination sewer cleaners, and hydro excavators; ice control products; snow plows and heavy duty snow removal equipment, hitches, attachments, and graders; landscape and vegetation maintenance equipment; and public works and runway maintenance products, parts, and services. In addition, the company offers rotary and finishing mowers, flail and disc mowers, front-end loaders, backhoes, rotary tillers, posthole diggers, scraper blades, and replacement parts, as well as zero turn radius mowers; cutting parts, plain and hard-faced replacement tillage tools, disc blades, and fertilizer application components; aftermarket agricultural parts; and heavy-duty mechanical rotary mowers, snow blowers, rock removal equipment, and replacement parts. Further, it provides tractor attachments; agricultural implements; hydraulic and boom-mounted hedge and grass cutters, and other tractor attachments and implements; hedgerow cutters, industrial grass mowers, and agricultural seedbed preparation cultivators; self-propelled sprayers and multi-drive load-carrying vehicles; cutting blades; hydraulic and mechanical boom mowers; and high pressure cleaning systems and trenchers. The company was founded in 1955 and is headquartered in Seguin, Texas.
Earnings Per Share
As for profitability, Alamo Group has a trailing twelve months EPS of $11.17.
PE Ratio
Alamo Group has a trailing twelve months price to earnings ratio of 16.45. Meaning, the purchaser of the share is investing $16.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.47%.
Moving Average
Alamo Group’s worth is higher than its 50-day moving average of $174.93 and higher than its 200-day moving average of $177.41.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Oct 12, 2023, the estimated forward annual dividend rate is 0.88 and the estimated forward annual dividend yield is 0.48%.
7. ePlus (PLUS)
6.4% sales growth and 17.41% return on equity
ePlus inc., together with its subsidiaries, provides information technology (IT) solutions that enable organizations to optimize their IT environment and supply chain processes in the United States and internationally. It operates in two segments, Technology and Financing. The Technology segment offers hardware, perpetual and subscription software, maintenance, software assurance, and internally provided and outsourced services; and professional and managed services, including ePlus managed, professional, security, ePlus cloud consulting, staff augmentation, server and desktop support, and project management services. The Financing segment specializes in financing arrangements, such as sales-type and operating leases; loans and consumption-based financing arrangements; and underwriting, management, and disposal of IT equipment and assets. Its financing operations comprise sales, pricing, credit, contracts, accounting, risk management, and asset management. This segment primarily finances IT, communication-related, and medical equipment; and industrial machinery and equipment, office furniture and general office equipment, transportation equipment, and other general business equipment directly, as well as through vendors. ePlus inc. serves commercial entities, state and local governments, government contractors, and educational institutions. The company was formerly known as MLC Holdings, Inc. and changed its name to ePlus inc. in 1999. ePlus inc. was founded in 1990 and is headquartered in Herndon, Virginia.
Earnings Per Share
As for profitability, ePlus has a trailing twelve months EPS of $5.06.
PE Ratio
ePlus has a trailing twelve months price to earnings ratio of 13.69. Meaning, the purchaser of the share is investing $13.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.41%.
Volume
Today’s last reported volume for ePlus is 94175 which is 12.95% below its average volume of 108195.
Yearly Top and Bottom Value
ePlus’s stock is valued at $69.26 at 19:22 EST, below its 52-week high of $75.90 and way higher than its 52-week low of $41.71.
8. Insperity (NSP)
5.6% sales growth and 264.61% return on equity
Insperity, Inc. engages in the provision of human resources (HR) and business solutions to improve business performance for small and medium-sized businesses. It offers its HR services through its Workforce Optimization and Workforce Synchronization solutions that include a range of human resources functions, such as payroll and employment administration, employee benefits, workers' compensation, government compliance, performance management, and training and development services. The company also provides Insperity Premier, a cloud-based human capital management platform that offers professional employer organization HR outsourcing solutions to its clients; people management services; and employer liability management services, as well as solutions for middle market. In addition, it offers MarketPlace, an e-commerce portal that offers a range of products and services; and Workforce Acceleration, a human capital management and payroll services solution; time and attendance; performance management; recruiting; employment screening; retirement; and insurance services. The company was formerly known as Administaff, Inc. and changed its name to Insperity, Inc. in March 2011. Insperity, Inc. was founded in 1986 and is headquartered in Kingwood, Texas.
Earnings Per Share
As for profitability, Insperity has a trailing twelve months EPS of $4.92.
PE Ratio
Insperity has a trailing twelve months price to earnings ratio of 23.48. Meaning, the purchaser of the share is investing $23.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 264.61%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 47.1% and a negative 5.6%, respectively.
Sales Growth
Insperity’s sales growth is 6.3% for the present quarter and 5.6% for the next.
Volume
Today’s last reported volume for Insperity is 151591 which is 33.77% below its average volume of 228919.
